GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Interest Coverage

Immunovia AB (OSTO:IMMNOV) Interest Coverage : 0 (At Loss) (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Immunovia AB's Operating Income for the three months ended in Mar. 2025 was kr-18.91 Mil. Immunovia AB's Interest Expense for the three months ended in Mar. 2025 was kr-38.91 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Immunovia AB's Interest Coverage or its related term are showing as below:


OSTO:IMMNOV's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 10.13
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Immunovia AB Interest Coverage Historical Data

The historical data trend for Immunovia AB's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Immunovia AB Interest Coverage Chart

Immunovia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunovia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunovia AB's Interest Coverage

For the Diagnostics & Research subindustry, Immunovia AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB's Interest Coverage Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Interest Coverage falls into.


;
;

Immunovia AB Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Immunovia AB's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Immunovia AB's Interest Expense was kr-1.86 Mil. Its Operating Income was kr-109.54 Mil. And its Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.

Immunovia AB did not have earnings to cover the interest expense.

Immunovia AB's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Immunovia AB's Interest Expense was kr-38.91 Mil. Its Operating Income was kr-18.91 Mil. And its Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.

Immunovia AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Immunovia AB  (OSTO:IMMNOV) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Immunovia AB Interest Coverage Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovia AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines